{"id":13207,"date":"2024-11-20T17:02:51","date_gmt":"2024-11-20T10:02:51","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=13207"},"modified":"2024-11-20T17:02:51","modified_gmt":"2024-11-20T10:02:51","slug":"singapore-medical-group-completes-s90m-bond-issuance-as-it-positions-for-a-new-phase-of-growth","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=13207","title":{"rendered":"Singapore Medical Group completes S$90m bond issuance as it positions for a new phase of growth"},"content":{"rendered":"<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2561787\/SMG_LOGO_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Issues <span class=\"xn-money\">S$90m<\/span> five-year senior unsecured bond bearing a fixed 3.54%\u00a0coupon, rated AA by S&amp;P Global Ratings<\/li>\n<li>Unconditionally and irrevocably guaranteed by the Credit Guarantee and Investment Facility (&#8220;CGIF&#8221;), a trust fund of the Asian Development Bank<\/li>\n<li>More than 4 times oversubscribed with very robust interest from leading global institutional investors<\/li>\n<li>Proceeds to be used towards refinancing existing loans and facilitate strategic expansion of its market leadership positions in key segments including diagnostic imaging, oncology and women&#8217;s health in <span class=\"xn-location\">Singapore<\/span> and across <span class=\"xn-location\">Asia<\/span><\/li>\n<li>Plans to leverage partnership with global\u00a0IVF leader CHA Medical Group and SMG&#8217;s pan-Pacific footprint to become a market leader in assisted reproductive medicine<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 20, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Singapore Medical Group (&#8220;SMG&#8221; or &#8220;the Group&#8221;), a multidisciplinary specialist healthcare services provider, has completed a <span class=\"xn-money\">S$90 million<\/span>, 5-year senior unsecured bond issuance at a 3.54% fixed rate due in 2029.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>The bond is unconditionally and irrevocably guaranteed by the Credit Guarantee and Investment Facility (&#8220;CGIF&#8221;), a trust fund of the Asian Development Bank, and assigned a rating of AA by S&amp;P Global Ratings.<\/p>\n<p>The issuance process generated robust market interest and was more than 4 times oversubscribed, backed by strong demand from leading global institutional investors including Blackrock, Aberdeen, Everspring, SingLife and Brunei Central Bank.<\/p>\n<p>The Group intends to use the net issuance proceeds to refinance existing loans, accelerate strategic expansion initiatives and allocate new capital expenditure for growth in <span class=\"xn-location\">Singapore<\/span> and the APAC region. \u00a0\u00a0<\/p>\n<p>DBS Bank Ltd and OCBC were the joint lead managers and bookrunners for the bond offering.<\/p>\n<p><b><i>Positioning for a New Phase of Regional Growth<\/i><\/b><\/p>\n<p>This latest corporate initiative effectively catalyses a new phase of growth as the Group embarks on the execution of several key strategies.<\/p>\n<p>Leveraging on its market leadership positioning in key segments such as diagnostic imaging, oncology, women&#8217;s and children&#8217;s health, SMG will continue to chart organic growth in <span class=\"xn-location\">Singapore<\/span> through the selective recruitment of new specialists, addition of new clinical footprints and service lines, and continued investments into technology and patient-oriented enhancements.<\/p>\n<p>Beyond <span class=\"xn-location\">Singapore<\/span>, the Group has successfully expanded into <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Vietnam<\/span> and <span class=\"xn-location\">Indonesia<\/span>. Near term, the Group expects to continue the strong momentum of exporting its brands to other high-growth markets across the ASEAN region. \u00a0On this front, the Group continues to seek collaborative opportunities with leading regional healthcare players and strategic partners to build a pan-Pacific patient base and network of cross-referrals.<\/p>\n<p>The Group intends to progressively expand its women&#8217;s and children&#8217;s health segments into a leading reproductive medicine provider in the region, with a strategic aim to deliver 15\u201320,000 IVF cycles annually in the next 3 years.<\/p>\n<p>This will be achieved by leveraging SMG&#8217;s long-term strategic partnership with its largest shareholder, CHA Medical Group (&#8220;CHA&#8221;), as well as the Group&#8217;s recent consolidation of City Fertility<sup>[1]<\/sup>, one of <span class=\"xn-location\">Australia&#8217;s<\/span> leading IVF groups. \u00a0\u00a0<\/p>\n<p>CHA Medical Group is widely renowned as one of the global leaders in IVF in terms of scale and clinical quality, and one of the leading comprehensive medical groups in the <span class=\"xn-location\">Asia Pacific<\/span> region with presence in Korea, <span class=\"xn-location\">Japan<\/span> and <span class=\"xn-location\">the United States<\/span>. \u00a0In Australia, City Fertility a national presence with 13 IVF clinics, 50+ consulting suites, dedicated day hospitals and more than 60 highly skilled fertility specialists practicing in key markets including <span class=\"xn-location\">Sydney<\/span>, <span class=\"xn-location\">Melbourne<\/span>, <span class=\"xn-location\">Brisbane<\/span> and <span class=\"xn-location\">Perth<\/span>.<\/p>\n<p>The Group aims to create apremier IVF network across the <span class=\"xn-location\">Asia Pacific<\/span> region by combining its strong relationships within key ASEAN markets, City Fertility&#8217;s growth-oriented platform in <span class=\"xn-location\">Australia<\/span> and CHA&#8217;s scale and scientific expertise in women&#8217;s health globally.<\/p>\n<p>Commenting on the announcement,<b> SMG&#8217;s CEO Dr. <span class=\"xn-person\">Beng Teck Liang<\/span><\/b> said, <i>&#8220;This inaugural bond issuance allows us to shore up and bolster our financial position as we look to aggressively scale the Group&#8217;s pan-Pacific healthcare platform. \u00a0With operations that span four countries today, we are excited about capturing growth opportunities in both existing and new high-growth geographies across our specialist verticals where we see clear and stable demand. \u00a0Accordingly, we are focused on the execution of both organic and inorganic growth strategies in <span class=\"xn-location\">Singapore<\/span> and the region with the ultimate goal of becoming the clear market leader in the specialist care space while evolving our current suite of services to focus more on women&#8217;s health and IVF.&#8221;<\/i><\/p>\n<p><b>Mr. <span class=\"xn-person\">Chris Chung<\/span>, CEO of CHA Asia, <\/b>added,\u00a0<i>&#8220;As a long-term strategic partner and shareholder of SMG, we are delighted with the exceptional investor interest and highly successful outcome of this bond offering.\u00a0 We believe it&#8217;s a clear reflection of investor recognition of SMG&#8217;s strategic achievements to date and strong confidence in its exciting future trajectory ahead.\u00a0 We&#8217;re eager to embark on the next phase of SMG&#8217;s journey and look forward to collaboratively building an unrivalled pan-Pacific franchise with an emphasis on further bolstering those segments where we can deliver unrivalled care excellence and exercise clear market leadership<span>.&#8221; <\/span><\/i><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb0 prnrbrb0 prnsbbb0 prnsblb0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><sup>[1]<\/sup>\u00a0PR Newswire, <a href=\"https:\/\/www.prnewswire.com\/apac\/news-releases\/singapore-medical-group-strengthens-presence-in-the-asia-pacific-region-with-controlling-stake-in-leading-australian-ivf-group-302224163.html\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">Singapore Medical Group strengthens presence in the Asia-Pacific region with controlling stake in leading Australian IVF group<\/a>, 16 August 2024<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>About Singapore Medical Group Limited (&#8220;SMG&#8221;)<\/b><\/p>\n<p>Incorporated in 2005 and formerly listed on the Singapore Stock Exchange, SMG is a private specialist healthcare provider headquartered in <span class=\"xn-location\">Singapore<\/span> with an extensive network of more than 45 owned and associated clinics covering over 25 medical specialties. \u00a0The Group has a growing regional presence in <span class=\"xn-location\">Ho Chi Minh City, Vietnam<\/span>, <span class=\"xn-location\">Jakarta<\/span>, and <span class=\"xn-location\">Surabaya<\/span> in <span class=\"xn-location\">Indonesia<\/span> and across multiple cities in <span class=\"xn-location\">Australia<\/span> following several investments and joint ventures with strategic partners.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/smg.sg\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/smg.sg\/<\/a><\/p>\n<p><b>About City Fertility (&#8220;CFC&#8221;)<\/b><\/p>\n<p>City Fertility is one of <span class=\"xn-location\">Australia&#8217;s<\/span> leading IVF &amp; reproductive medicine groups with 13 IVF clinics, 50+ consulting suites, dedicated day hospitals and more than 60 highly skilled fertility specialists practicing nationwide across <span class=\"xn-location\">Queensland<\/span>, <span class=\"xn-location\">Victoria<\/span>, <span class=\"xn-location\">New South Wales<\/span> and <span class=\"xn-location\">Western Australia<\/span>. CFC provides seamless care across the full fertility spectrum for patients of all backgrounds, including international. CFC also offers a comprehensive range of support services including social egg freezing, surrogacy, sperm &amp; egg donor programs, genetic testing and LGBT-friendly treatments. City Fertility is driven by cutting-edge research and global medical innovation alongside CHA Medical Group and delivers top-tier success rates using the latest advances in reproductive medicine.\u00a0 \u00a0<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.cityfertility.com.au\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.cityfertility.com.au<\/a> \u00a0<\/p>\n<p><b>About CHA Medical Group (&#8220;CHA&#8221;)<\/b><\/p>\n<p>Headquartered in Korea, CHA is one of <span class=\"xn-location\">Asia&#8217;s<\/span> leading private medical groups encompassing the full healthcare spectrum from research and education to hospital- and clinic-based care.\u00a0 CHA has a comprehensive healthcare platform including:<\/p>\n<ul type=\"disc\">\n<li>16 general &amp; specialty hospitals with approximately 2,300 beds;<\/li>\n<li>23 research and educational institutions, including CHA University School of Medicine;<\/li>\n<li>Footprint in 7 countries including Korea, <span class=\"xn-location\">Japan<\/span> and the US<\/li>\n<\/ul>\n<p>CHA today handles more than 2.5 million outpatient visits and 450,000 inpatient admissions annually, with a talent pool of approximately 1,500 physicians and 3,000 nurses globally.\u00a0 CHA is widely renowned as a global leader in IVF and reproductive medicine, both through excellence in clinical research and in patient care.\u00a0 As Asia&#8217;s leading experts in infertility, women&#8217;s health and maternity care, CHA provides over 12,000 deliveries and approximately 50,000 IVF cycles annually. \u00a0Key landmark achievements include Korea&#8217;s first successful delivery of a test-tube baby at a private hospital in 1986, the world&#8217;s first pregnancy and birth using immature oocytes in 1989, the world&#8217;s first successful pregnancy and birth through vitrification method for oocyte cryopreservation in 1998 and the establishment of the world&#8217;s first egg bank in 1999, as well as numerous international academic accolades for pioneering research.<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2561787\/SMG_LOGO_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<ul type=\"disc\">\n<li>Issues <span class=\"xn-money\">S$90m<\/span> five-year senior unsecured bond bearing a fixed 3.54%\u00a0coupon, rated AA by S&amp;P Global Ratings<\/li>\n<li>Unconditionally and irrevocably guaranteed by the Credit Guarantee and Investment Facility (&#8220;CGIF&#8221;), a trust fund of the Asian Development Bank<\/li>\n<li>More than 4 times oversubscribed with very robust interest from leading global institutional investors<\/li>\n<li>Proceeds to be used towards refinancing existing loans and facilitate strategic expansion of its market leadership positions in key segments including diagnostic imaging, oncology and women&#8217;s health in <span class=\"xn-location\">Singapore<\/span> and across <span class=\"xn-location\">Asia<\/span><\/li>\n<li>Plans to leverage partnership with global\u00a0IVF leader CHA Medical Group and SMG&#8217;s pan-Pacific footprint to become a market leader in assisted reproductive medicine<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SINGAPORE<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 20, 2024<\/span><\/span> \/PRNewswire\/ &#8212; Singapore Medical Group (&#8220;SMG&#8221; or &#8220;the Group&#8221;), a multidisciplinary specialist healthcare services provider, has completed a <span class=\"xn-money\">S$90 million<\/span>, 5-year senior unsecured bond issuance at a 3.54% fixed rate due in 2029.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<\/div>\n<p>The bond is unconditionally and irrevocably guaranteed by the Credit Guarantee and Investment Facility (&#8220;CGIF&#8221;), a trust fund of the Asian Development Bank, and assigned a rating of AA by S&amp;P Global Ratings.<\/p>\n<p>The issuance process generated robust market interest and was more than 4 times oversubscribed, backed by strong demand from leading global institutional investors including Blackrock, Aberdeen, Everspring, SingLife and Brunei Central Bank.<\/p>\n<p>The Group intends to use the net issuance proceeds to refinance existing loans, accelerate strategic expansion initiatives and allocate new capital expenditure for growth in <span class=\"xn-location\">Singapore<\/span> and the APAC region. \u00a0\u00a0<\/p>\n<p>DBS Bank Ltd and OCBC were the joint lead managers and bookrunners for the bond offering.<\/p>\n<p><b><i>Positioning for a New Phase of Regional Growth<\/i><\/b><\/p>\n<p>This latest corporate initiative effectively catalyses a new phase of growth as the Group embarks on the execution of several key strategies.<\/p>\n<p>Leveraging on its market leadership positioning in key segments such as diagnostic imaging, oncology, women&#8217;s and children&#8217;s health, SMG will continue to chart organic growth in <span class=\"xn-location\">Singapore<\/span> through the selective recruitment of new specialists, addition of new clinical footprints and service lines, and continued investments into technology and patient-oriented enhancements.<\/p>\n<p>Beyond <span class=\"xn-location\">Singapore<\/span>, the Group has successfully expanded into <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">Vietnam<\/span> and <span class=\"xn-location\">Indonesia<\/span>. Near term, the Group expects to continue the strong momentum of exporting its brands to other high-growth markets across the ASEAN region. \u00a0On this front, the Group continues to seek collaborative opportunities with leading regional healthcare players and strategic partners to build a pan-Pacific patient base and network of cross-referrals.<\/p>\n<p>The Group intends to progressively expand its women&#8217;s and children&#8217;s health segments into a leading reproductive medicine provider in the region, with a strategic aim to deliver 15\u201320,000 IVF cycles annually in the next 3 years.<\/p>\n<p>This will be achieved by leveraging SMG&#8217;s long-term strategic partnership with its largest shareholder, CHA Medical Group (&#8220;CHA&#8221;), as well as the Group&#8217;s recent consolidation of City Fertility<sup>[1]<\/sup>, one of <span class=\"xn-location\">Australia&#8217;s<\/span> leading IVF groups. \u00a0\u00a0<\/p>\n<p>CHA Medical Group is widely renowned as one of the global leaders in IVF in terms of scale and clinical quality, and one of the leading comprehensive medical groups in the <span class=\"xn-location\">Asia Pacific<\/span> region with presence in Korea, <span class=\"xn-location\">Japan<\/span> and <span class=\"xn-location\">the United States<\/span>. \u00a0In Australia, City Fertility a national presence with 13 IVF clinics, 50+ consulting suites, dedicated day hospitals and more than 60 highly skilled fertility specialists practicing in key markets including <span class=\"xn-location\">Sydney<\/span>, <span class=\"xn-location\">Melbourne<\/span>, <span class=\"xn-location\">Brisbane<\/span> and <span class=\"xn-location\">Perth<\/span>.<\/p>\n<p>The Group aims to create apremier IVF network across the <span class=\"xn-location\">Asia Pacific<\/span> region by combining its strong relationships within key ASEAN markets, City Fertility&#8217;s growth-oriented platform in <span class=\"xn-location\">Australia<\/span> and CHA&#8217;s scale and scientific expertise in women&#8217;s health globally.<\/p>\n<p>Commenting on the announcement,<b> SMG&#8217;s CEO Dr. <span class=\"xn-person\">Beng Teck Liang<\/span><\/b> said, <i>&#8220;This inaugural bond issuance allows us to shore up and bolster our financial position as we look to aggressively scale the Group&#8217;s pan-Pacific healthcare platform. \u00a0With operations that span four countries today, we are excited about capturing growth opportunities in both existing and new high-growth geographies across our specialist verticals where we see clear and stable demand. \u00a0Accordingly, we are focused on the execution of both organic and inorganic growth strategies in <span class=\"xn-location\">Singapore<\/span> and the region with the ultimate goal of becoming the clear market leader in the specialist care space while evolving our current suite of services to focus more on women&#8217;s health and IVF.&#8221;<\/i><\/p>\n<p><b>Mr. <span class=\"xn-person\">Chris Chung<\/span>, CEO of CHA Asia, <\/b>added,\u00a0<i>&#8220;As a long-term strategic partner and shareholder of SMG, we are delighted with the exceptional investor interest and highly successful outcome of this bond offering.\u00a0 We believe it&#8217;s a clear reflection of investor recognition of SMG&#8217;s strategic achievements to date and strong confidence in its exciting future trajectory ahead.\u00a0 We&#8217;re eager to embark on the next phase of SMG&#8217;s journey and look forward to collaboratively building an unrivalled pan-Pacific franchise with an emphasis on further bolstering those segments where we can deliver unrivalled care excellence and exercise clear market leadership<span>.&#8221; <\/span><\/i><\/p>\n<div>\n<table border=\"0\" cellspacing=\"0\" cellpadding=\"1\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prnpr2 prnpl2 prnvab prnsbtb0 prnrbrb0 prnsbbb0 prnsblb0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"prnml4\"><span class=\"prnews_span\"><sup>[1]<\/sup>\u00a0PR Newswire, <a href=\"https:\/\/www.prnewswire.com\/apac\/news-releases\/singapore-medical-group-strengthens-presence-in-the-asia-pacific-region-with-controlling-stake-in-leading-australian-ivf-group-302224163.html\" target=\"_blank\" class=\"prnews_a\" rel=\"nofollow\">Singapore Medical Group strengthens presence in the Asia-Pacific region with controlling stake in leading Australian IVF group<\/a>, 16 August 2024<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><b>About Singapore Medical Group Limited (&#8220;SMG&#8221;)<\/b><\/p>\n<p>Incorporated in 2005 and formerly listed on the Singapore Stock Exchange, SMG is a private specialist healthcare provider headquartered in <span class=\"xn-location\">Singapore<\/span> with an extensive network of more than 45 owned and associated clinics covering over 25 medical specialties. \u00a0The Group has a growing regional presence in <span class=\"xn-location\">Ho Chi Minh City, Vietnam<\/span>, <span class=\"xn-location\">Jakarta<\/span>, and <span class=\"xn-location\">Surabaya<\/span> in <span class=\"xn-location\">Indonesia<\/span> and across multiple cities in <span class=\"xn-location\">Australia<\/span> following several investments and joint ventures with strategic partners.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/smg.sg\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/smg.sg\/<\/a><\/p>\n<p><b>About City Fertility (&#8220;CFC&#8221;)<\/b><\/p>\n<p>City Fertility is one of <span class=\"xn-location\">Australia&#8217;s<\/span> leading IVF &amp; reproductive medicine groups with 13 IVF clinics, 50+ consulting suites, dedicated day hospitals and more than 60 highly skilled fertility specialists practicing nationwide across <span class=\"xn-location\">Queensland<\/span>, <span class=\"xn-location\">Victoria<\/span>, <span class=\"xn-location\">New South Wales<\/span> and <span class=\"xn-location\">Western Australia<\/span>. CFC provides seamless care across the full fertility spectrum for patients of all backgrounds, including international. CFC also offers a comprehensive range of support services including social egg freezing, surrogacy, sperm &amp; egg donor programs, genetic testing and LGBT-friendly treatments. City Fertility is driven by cutting-edge research and global medical innovation alongside CHA Medical Group and delivers top-tier success rates using the latest advances in reproductive medicine.\u00a0 \u00a0<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.cityfertility.com.au\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.cityfertility.com.au<\/a> \u00a0<\/p>\n<p><b>About CHA Medical Group (&#8220;CHA&#8221;)<\/b><\/p>\n<p>Headquartered in Korea, CHA is one of <span class=\"xn-location\">Asia&#8217;s<\/span> leading private medical groups encompassing the full healthcare spectrum from research and education to hospital- and clinic-based care.\u00a0 CHA has a comprehensive healthcare platform including:<\/p>\n<ul type=\"disc\">\n<li>16 general &amp; specialty hospitals with approximately 2,300 beds;<\/li>\n<li>23 research and educational institutions, including CHA University School of Medicine;<\/li>\n<li>Footprint in 7 countries including Korea, <span class=\"xn-location\">Japan<\/span> and the US<\/li>\n<\/ul>\n<p>CHA today handles more than 2.5 million outpatient visits and 450,000 inpatient admissions annually, with a talent pool of approximately 1,500 physicians and 3,000 nurses globally.\u00a0 CHA is widely renowned as a global leader in IVF and reproductive medicine, both through excellence in clinical research and in patient care.\u00a0 As Asia&#8217;s leading experts in infertility, women&#8217;s health and maternity care, CHA provides over 12,000 deliveries and approximately 50,000 IVF cycles annually. \u00a0Key landmark achievements include Korea&#8217;s first successful delivery of a test-tube baby at a private hospital in 1986, the world&#8217;s first pregnancy and birth using immature oocytes in 1989, the world&#8217;s first successful pregnancy and birth through vitrification method for oocyte cryopreservation in 1998 and the establishment of the world&#8217;s first egg bank in 1999, as well as numerous international academic accolades for pioneering research.<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-13207","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13207"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/13207\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}